Kim Pettersson

ORCID: 0000-0002-3749-5591 · 4 papers in corpus
article 2020
Exploratory Analysis of CA125-MGL and –STn Glycoforms in the Differential Diagnostics of Pelvic Masses
The journal of applied laboratory medicine ·doi:10.1093/jalm/jfz012

BACKGROUND: The cancer antigen 125 (CA125) immunoassay (IA) does not distinguish epithelial ovarian cancer (EOC) from benign disease with the sensitivity needed in clinical practice. In recent studies, glycoforms of CA125 have shown potenti…

2020
Glycovariant-based lateral flow immunoassay to detect ovarian cancer-associated serum CA125.
Communications biology ·doi:10.1038/s42003-020-01191-x

Cancer antigen 125 (CA125) is a widely used biomarker in monitoring of epithelial ovarian cancer (EOC). Due to insufficient cancer specificity of CA125, its diagnostic use is severely compromised. Abnormal glycosylation of CA125 is a unique…

other 2019
Europium Nanoparticle-Based Sialyl-Tn Monoclonal Antibody Discriminates Epithelial Ovarian Cancer-Associated CA125 from Benign Sources
The journal of applied laboratory medicine ·doi:10.1373/jalm.2018.028266

BACKGROUND: The Sialyl-Thomsen-nouveau antigen (STn) is abundantly produced on many types of human epithelial cancers including epithelial ovarian cancer (EOC). We previously developed an EOC-specific lectin sandwich immunoassay (CA125MGL) …

other 2016
A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources
Clinical chemistry ·doi:10.1373/clinchem.2016.257691

BACKGROUND: Measurement of serum cancer antigen 125 (CA125) is the standard approach for epithelial ovarian cancer (EOC) diagnostics and follow-up. However, the clinical specificity is not optimal because increased values are also detected …